RESUMO
AIMS: To describe the natural history of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. METHODS AND RESULTS: Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS-Cov-2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS-CoV-2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty-nine (22.9%) HCM patients were hospitalized for non-ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS-CoV-2-related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12-4.51], P = 0.0229}, baseline New York Heart Association class [OR per one-unit increase 4.01 (95%CI: 1.75-9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16-26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20-49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community-based SARS-CoV-2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98-2.91, P = 0.0600). CONCLUSIONS: Over one-fourth of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.
Assuntos
Fibrilação Atrial , COVID-19 , Cardiomiopatia Hipertrófica , Disfunção Ventricular Esquerda , Humanos , Masculino , Adulto , Pessoa de Meia-Idade , Idoso , Feminino , COVID-19/complicações , COVID-19/epidemiologia , SARS-CoV-2 , Cardiomiopatia Hipertrófica/complicações , Cardiomiopatia Hipertrófica/epidemiologia , Sistema de Registros , Disfunção Ventricular Esquerda/complicações , Fibrilação Atrial/complicaçõesRESUMO
INTRODUCTION AND OBJECTIVES: Hereditary transthyretin amyloidosis (hATTR) is a disease caused by mutations in the transthyretin gene that frequently shows cardiac involvement due to amyloid deposition in the myocardium. Our objective was to identify cardiac involvement in a Spanish cohort. METHODS: Retrospective multicenter study of patients diagnosed with hATTR with cardiac involvement from Spanish centers. We collected demographic, clinical, and genetic data. RESULTS: A total of 181 patients from 26 centers were included (65.2% men, with a median age at diagnosis of 62 years). The most frequent mutations were Val50Met (67.7%) and Val142Ile (12.4%). The main reason for consultation was extracardiac symptoms (69%), mainly neurological. The mean N-terminal pro-B-type natriuretic peptide level was 2145±3586 pg/mL. The most characteristic electrocardiogram findings were a pseudoinfarct pattern (25.9%) and atrioventricular block (25.3%). Mean ventricular thickness was 15.4±4.1mm. Longitudinal strain was reduced in basal segments by 29.4%. Late diffuse subendocardial enhancement was observed in 58.8%. Perugini grade 2 or 3 uptake was observed in 75% of scintigraphy scans. During follow-up, 24.9% of the patients were admitted for heart failure, 34.3% required a pacemaker, and 31.6% required a liver transplant. One third (32.5%) died during follow-up, mainly due to heart failure (28.8%). The presence of non-Val50Met mutations was associated with a worse prognosis. CONCLUSIONS: HATTR cardiac amyloidosis in Spain shows heterogeneous genetic and clinical involvement. The prognosis is poor, mainly due to cardiac complications. Consequently early diagnosis and treatment are vital.
Assuntos
Neuropatias Amiloides Familiares , Cardiomiopatias , Insuficiência Cardíaca , Neuropatias Amiloides Familiares/diagnóstico , Neuropatias Amiloides Familiares/epidemiologia , Neuropatias Amiloides Familiares/genética , Cardiomiopatias/diagnóstico , Cardiomiopatias/epidemiologia , Cardiomiopatias/genética , Feminino , Insuficiência Cardíaca/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Pré-Albumina/genética , Espanha/epidemiologiaRESUMO
Introducción y objetivos: La enfermedad de Danon (ED) es una enfermedad producida por mutaciones en el gen LAMP2. Se la considera una enfermedad multisistémica caracterizada por miocardiopatía hipertrófica con preexcitación e hipertrofia extrema, discapacidad intelectual, miopatía, presentación infantil y peor pronóstico en varones. Hay pocas series que permitan conocer las características clínicas y el pronóstico de la ED. Métodos: Se analizaron los registros clínicos de los pacientes con ED de 10 hospitales españoles. Resultados: Se incluyó a 27 pacientes (edad, 31 +/- 19 años; el 78% mujeres). Los varones mostraron una elevada prevalencia de manifestaciones extracardiacas -miopatía (80%), trastornos del aprendizaje (83%) y alteraciones visuales (60%)- que eran infrecuentes en las mujeres (el 5, el 0 y el 27% respectivamente). Aunque la miocardiopatía hipertrófica era la cardiopatía más habitual (61%), el grosor ventricular máximo fue 15 +/- 7 mm y 12 pacientes (10 mujeres) presentaron miocardiopatía dilatada. Solo 11 pacientes (49%) mostraron preexcitación y en 16 (65%) la enfermedad se inició después de los 20 años. Tras una mediana de seguimiento de 4 años [intervalo intercuartílico, 2-9], 4 varones (67%) y 9 mujeres (43%) fallecieron o se sometieron a trasplante. El daño cardiaco y los eventos adversos ocurrieron más tardíamente en las mujeres (37 +/- 9 frente a 23 +/- 16 años y 36 +/- 20 frente a 20 +/- 11 años). Conclusiones: Las características clínicas de la ED difieren sustancialmente de lo considerado tradicionalmente. La edad de presentación de la ED es más tardía, no se expresa como una enfermedad multisistémica en las mujeres y la preexcitación es poco frecuente
Introduction and objectives: Danon disease (DD) is caused by mutations in the LAMP2 gene. It is considered a multisystemic disease characterized by hypertrophic cardiomyopathy with pre-excitation and extreme hypertrophy, intellectual disability, myopathy, childhood presentation, and worse prognosis in men. There are scarce data on the clinical characteristics and prognosis of DD. Methods: We analyzed the clinical records of patients with DD from 10 Spanish hospitals. Results: Twenty-seven patients were included (mean age, 31 +/- 19 years; 78% women). Male patients showed a high prevalence of extracardiac manifestations: myopathy (80%), learning disorders (83%), and visual alterations (60%), which were uncommon findings in women (5%, 0%, and 27%, respectively). Although hypertrophic cardiomyopathy was the most common form of heart disease (61%), the mean maximum wall thickness was 15 +/- 7 mm and dilated cardiomyopathy was present in 12 patients (10 women). Pre-excitation was found in only 11 patients (49%). Age at presentation was older than 20 years in 16 patients (65%). After a median follow-up of 4 years (interquartile range, 2-9), 4 men (67%) and 9 women (43%) died or required a transplant. Cardiac disease and adverse events occurred later in women (37 +/- 9 vs 23 +/- 16 and 36 +/- 20 vs 20 +/- 11 years, respectively). Conclusions: The clinical characteristics of DD differ substantially from traditional descriptions: age at presentation of DD is older, the disease is not multisystemic in women, and pre-excitation is infrequent
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Cardiomiopatia Hipertrófica/complicações , Síndromes de Pré-Excitação/complicações , Cardiomegalia/complicações , Deficiência Intelectual/complicações , Eletrocardiografia/estatística & dados numéricos , Registros de Doenças/estatística & dados numéricos , Síncope/etiologia , Dor no Peito/etiologia , Insuficiência Cardíaca/diagnósticoRESUMO
INTRODUCTION AND OBJECTIVES: Danon disease (DD) is caused by mutations in the LAMP2 gene. It is considered a multisystemic disease characterized by hypertrophic cardiomyopathy with pre-excitation and extreme hypertrophy, intellectual disability, myopathy, childhood presentation, and worse prognosis in men. There are scarce data on the clinical characteristics and prognosis of DD. METHODS: We analyzed the clinical records of patients with DD from 10 Spanish hospitals. RESULTS: Twenty-seven patients were included (mean age, 31 ± 19 years; 78% women). Male patients showed a high prevalence of extracardiac manifestations: myopathy (80%), learning disorders (83%), and visual alterations (60%), which were uncommon findings in women (5%, 0%, and 27%, respectively). Although hypertrophic cardiomyopathy was the most common form of heart disease (61%), the mean maximum wall thickness was 15 ± 7 mm and dilated cardiomyopathy was present in 12 patients (10 women). Pre-excitation was found in only 11 patients (49%). Age at presentation was older than 20 years in 16 patients (65%). After a median follow-up of 4 years (interquartile range, 2-9), 4 men (67%) and 9 women (43%) died or required a transplant. Cardiac disease and adverse events occurred later in women (37 ± 9 vs 23 ± 16 and 36 ± 20 vs 20 ± 11 years, respectively). CONCLUSIONS: The clinical characteristics of DD differ substantially from traditional descriptions: age at presentation of DD is older, the disease is not multisystemic in women, and pre-excitation is infrequent.
Assuntos
Cardiomiopatia Hipertrófica/etiologia , Doença de Depósito de Glicogênio Tipo IIb/diagnóstico , Sistema de Registros , Síndrome de Wolff-Parkinson-White/etiologia , Adolescente , Adulto , Cardiomiopatia Hipertrófica/diagnóstico , Cardiomiopatia Hipertrófica/epidemiologia , Eletrocardiografia , Feminino , Doença de Depósito de Glicogênio Tipo IIb/complicações , Doença de Depósito de Glicogênio Tipo IIb/genética , Humanos , Incidência , Proteína 2 de Membrana Associada ao Lisossomo/genética , Proteína 2 de Membrana Associada ao Lisossomo/metabolismo , Masculino , Mutação , Fenótipo , Prognóstico , Estudos Retrospectivos , Espanha/epidemiologia , Síndrome de Wolff-Parkinson-White/diagnóstico , Síndrome de Wolff-Parkinson-White/epidemiologia , Adulto JovemRESUMO
La muerte súbita es fundamentalmente cardiaca y tiene un gran impacto social, económico y mediático. Cuando acontece en personas jóvenes, suele obedecer a causas genéticas (cardiopatías familiares). En este grupo se incluyen las miocardiopatías, canalopatías y el aneurisma/disección aórtica familiar. Las cardiopatías familiares son enfermedades raras en términos de prevalencia y poco conocidas, por lo que su manejo requiere formación especializada y multidisciplinar. La muerte súbita suele acontecer en el ámbito extrahospitalario y es objeto de una autopsia forense. Estas autopsias deberían realizarse de acuerdo a los estándares mínimos de calidad de las guías europeas. El claro sustrato genético justifica la necesidad de un screening familiar para realizar diagnósticos precoces y también para descartarla en otros familiares en riesgo a través de un abordaje multidisciplinar que ofrezca una medicina personalizada a las familias afectadas. Además de las cuestiones médicas, este esquema permite ofrecer apoyo psicológico precoz y consejo genético de cara a planificar nuevas gestaciones. En España existe un gran vacío legal en el abordaje de la muerte súbita y su prevención, con una falta de homogenización entre las distintas comunidades autónomas tanto a nivel judicial como asistencial debido a las características del proceso de transferencia de competencias y a la organización territorial judicial y forense. Sería deseable que, desde los órganos consultivos de ambos ministerios (Sanidad y Justicia) se elaborara un plan de actuación global que asegurara la calidad en el estudio post mortem y su continuidad en el posterior estudio familiar clínico y genético. Así, el potencial clínico-preventivo de las autopsias tomaría cuerpo y revertiría en un claro beneficio para las familias afectadas y para la sociedad en general favoreciendo asimismo la docencia y la investigación, tan importantes para el avance del conocimiento en este ámbito tan desconocido y devastador (AU)
Cardiac diseases often underlie sudden deaths. Sudden death has a great social and economic impact and generates loads of media attention. When it occurs in young people, it is usually due to genetic causes (inherited heart diseases). This group includes cardiomyopathies, channelopathies, and familial thoracic aortic aneurysm/dissection. Inherited heart conditions are rare diseases in terms of prevalence and little knowledge is still available from most of them, so their management requires specialised and multidisciplinary training. Sudden death usually occurs in the out-of-hospital setting, and there has to be a forensic autopsy. These autopsies should be performed according to the minimum quality standards of the European guidelines. The clear genetic background justifies the need for a family screening to enable early diagnosis and also to rule it out in other family members at risk using a multidisciplinary approach offering personalised medicine to the affected families. In addition to medical issues, this scheme enables the provision of early psychological support and genetic counseling to plan new gestations. In Spain there is a great legal void in the approach to sudden death and its prevention, with a lack of homogenisation among the different counties, both at the judicial and healthcare levels due to the variable recognition of acquired skills and to the differences in the judicial and territorial forensic organisation throughout the country. It would be desirable that the consultative panels of both Ministries (Health and Justice) developed a comprehensive plan to ensure the quality in post-mortem studies and a proper subsequent clinical and genetic family study in public health services. Thus, the clinical-preventive potential of the autopsies would take shape and become a clear benefit for the affected families and for the society in general. This measure would also favour the teaching and the research of inherited cardiac diseases, which is of paramount importance to improve the current knowledge in this field, so unknown and so devastating (AU)
Assuntos
Humanos , Morte Súbita Cardíaca/prevenção & controle , Cardiopatias Congênitas/complicações , Ambulatório Hospitalar/organização & administração , Equipe de Assistência ao Paciente/organização & administração , Patologia Legal/tendências , Autopsia/métodosRESUMO
La muerte súbita se define como el fallecimiento inesperado que acontece antes de una hora desde el inicio de los síntomas, este tipo de muerte tiene un alto impacto social, mediático y económico. La primera causa es la de origen cardíaco y dentro de estas la cardiopatía isquémica es la más frecuente, pero las cardiopatías familiares (canalopatías y miocardiopatías) son porcentualmente más importantes en niños y jóvenes, donde representan la primera causa de muerte súbita cardíaca. Estas cardiopatías familiares tienen un claro sustrato genético que justifica la indicación de un adecuado estudio de los familiares de los fallecidos. De acuerdo a los datos de la población española del censo de 2013 (46,7 millones de habitantes) en la comunidad valenciana, que representa el 10% de esta población, se estima que residen 20000 personas con alguna cardiopatía familiar potencialmente letal. Dada la importancia y el impacto social de la muerte súbita de origen cardíaco, y puesto que la autopsia médico-legal tiene limitaciones para diagnosticar la enfermedad subyacente en este tipo de muertes, la estrategia más oportuna es el enfoque multidisciplinar, motivo por el cual en el año 2008 se creó la Unidad de Muerte Súbita Familiar y Cardiopatías Familiares en esta región
The sudden death is defined as the unexpected death that occurs within an hour of the onset of symptoms. This type of death has a high social, media and economic impact. The first cause is of cardiac origin, and within this, the ischemic heart disease is the most frequent, but family heart diseases (channelopathies and cardiomyopathies) are more important in children and young people, where they represent the first cause of sudden cardiac death. These family heart diseases have a clear genetic substrate that justifies the indication of an adequate study of the relatives of the deceased. According to the data of the Spanish population of the 2013 census (46.7 million inhabitants) in the Valencian Community, which represents 10% of this population, it is estimated that there are 20.000 people with some potentially lethal heart disease. Given the importance and the social impact of sudden death of cardiac origin, and since the medical-legal autopsy has limitations to diagnose the underlying disease in these types of deaths, the most opportune strategy is the multidisciplinary approach, which is why in 2008, the Family Sudden Death and Family Heart Diseases Unit was created in this region
Assuntos
Morte Súbita Cardíaca , Fatores de Risco , Diagnóstico , Prevenção de Doenças , CardiopatiasAssuntos
Apego ao Objeto , Psicopatologia , Estresse Psicológico , Pesar , Fatores de Risco , Fatores de ProteçãoRESUMO
Con el término cardiopatías familiares se designa un grupo de enfermedades cardiovasculares (miocardiopatías, canalopatías, algunas enfermedades aórticas y otros síndromes) que comparten una serie de características comunes: tienen una base genética, una presentación familiar, un curso clínico heterogéneo y, por último, todas pueden relacionarse con la muerte súbita. El presente documento recoge de forma resumida algunos conceptos importantes en relación con los avances recientes en las técnicas de secuenciación y el conocimiento de las bases genéticas de estas enfermedades. Se proponen algoritmos diagnósticos y recomendaciones prácticas y se debaten aspectos de interés clínico controvertidos y actuales. Se resalta el papel de las unidades de referencia multidisciplinares para diagnosticarlas y tratarlas (AU)
The term inherited cardiovascular disease encompasses a group of cardiovascular diseases (cardiomyopathies, channelopathies, certain aortic diseases, and other syndromes) with a number of common characteristics: they have a genetic basis, a familial presentation, a heterogeneous clinical course, and, finally, can all be associated with sudden cardiac death. The present document summarizes some important concepts related to recent advances in sequencing techniques and understanding of the genetic bases of these diseases. We propose diagnostic algorithms and clinical practice recommendations and discuss controversial aspects of current clinical interest. We highlight the role of multidisciplinary referral units in the diagnosis and treatment of these conditions (AU)
Assuntos
Humanos , Síndrome de Marfan/terapia , Canalopatias/terapia , Morte Súbita Cardíaca/prevenção & controle , Cardiomiopatias/terapia , Protocolos Clínicos , Guias de Prática Clínica como Assunto , Marcadores Genéticos , Estudos de Associação Genética/métodosRESUMO
The term inherited cardiovascular disease encompasses a group of cardiovascular diseases (cardiomyopathies, channelopathies, certain aortic diseases, and other syndromes) with a number of common characteristics: they have a genetic basis, a familial presentation, a heterogeneous clinical course, and, finally, can all be associated with sudden cardiac death. The present document summarizes some important concepts related to recent advances in sequencing techniques and understanding of the genetic bases of these diseases. We propose diagnostic algorithms and clinical practice recommendations and discuss controversial aspects of current clinical interest. We highlight the role of multidisciplinary referral units in the diagnosis and treatment of these conditions.
Assuntos
Algoritmos , Doenças Cardiovasculares/terapia , Morte Súbita Cardíaca/prevenção & controle , Arritmias Cardíacas/complicações , Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/genética , Arritmias Cardíacas/terapia , Síndrome de Brugada/complicações , Síndrome de Brugada/diagnóstico , Síndrome de Brugada/genética , Síndrome de Brugada/terapia , Cardiomiopatia Dilatada/complicações , Cardiomiopatia Dilatada/diagnóstico , Cardiomiopatia Dilatada/genética , Cardiomiopatia Dilatada/terapia , Cardiomiopatia Hipertrófica Familiar/complicações , Cardiomiopatia Hipertrófica Familiar/diagnóstico , Cardiomiopatia Hipertrófica Familiar/genética , Cardiomiopatia Hipertrófica Familiar/terapia , Doenças Cardiovasculares/complicações , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/genética , Canalopatias/complicações , Canalopatias/diagnóstico , Canalopatias/genética , Canalopatias/terapia , Morte Súbita Cardíaca/etiologia , Predisposição Genética para Doença , Humanos , Síndrome de Loeys-Dietz/complicações , Síndrome de Loeys-Dietz/diagnóstico , Síndrome de Loeys-Dietz/genética , Síndrome de Loeys-Dietz/terapia , Síndrome do QT Longo/complicações , Síndrome do QT Longo/diagnóstico , Síndrome do QT Longo/genética , Síndrome do QT Longo/terapia , Síndrome de Marfan/complicações , Síndrome de Marfan/diagnóstico , Síndrome de Marfan/genética , Síndrome de Marfan/terapia , Guias de Prática Clínica como Assunto , Taquicardia Ventricular/complicações , Taquicardia Ventricular/diagnóstico , Taquicardia Ventricular/genética , Taquicardia Ventricular/terapiaRESUMO
The aim of this study was to use magnetic resonance imaging (MRI) to classify the morphological changes and remodeling of the right ventricle (RV) that occur in different clinical situations and that have an impact on RV function. Most literature has traditionally focused on the left ventricle (LV) and as a result, few studies analyze RV behavior and remodeling. The study evaluated all cardiac MRI performed at our center from 2008 to 2010. We retrospectively identified 159 patients who had some sign of right ventricular dysfunction (RVD) based on MRI findings. We classified patients according to a combination of criteria for RVD and the presence of left ventricle dysfunction (LVD). We considered RVD as any of the following abnormalities: i) depressed RV function; ii) RV dilatation; iii) RV hypertrophy. LVD was considered when there was atrial dilatation, LV hypertrophy, LV dilatation and/or depressed LV function. We obtained 6 pathophysiological patterns: RV pressure overload (1.9%), RV volume overload (15.7%), RV volume overload + LVD (32.7%), depressed RV function + LVD (42.1%), mixed RV overload + LVD (6.9%) and other (0.6%). The most frequent etiology was congenital heart disease (33.3%), followed by idiopathic dilated cardiomyopathy (18.2%), left valvular disease (17.6%), ischemic heart disease (15%), pulmonary disease (9.8%), and other (6.1%). This study helps to classify the different patterns that RV can adopt in different clinical situations and can, therefore, help us to understand the RV pathophysiology.
RESUMO
Protein-losing enteropathy is a rare but life-threatening complication that occurs in some patients who develop intestinal lymphangiectasis secondary to increased systemic venous pressure. Although different forms of treatment have been tried, with varying results, the majority were reported to be unsuccessful. The aim of this study was to demonstrate that heart transplantation may be an appropriate therapeutic option for patients who do not respond to medical treatment. At our center, we performed heart transplantations in three patients with this condition. The mean follow-up period was 11+/-2 months. No patient died and the enteropathy regressed in all three.
Assuntos
Transplante de Coração , Enteropatias Perdedoras de Proteínas/cirurgia , Adolescente , Feminino , Humanos , Masculino , Indução de RemissãoRESUMO
La enteropatía pierdeproteínas es una infrecuente pero muy grave complicación que aparece en determinados pacientes que desarrollan linfangiectasia intestinal secundaria a un incremento de la presión venosa sistémica. Se han descrito diferentes tratamientos, con resultados dispares y en la mayoría de las ocasiones sin respuesta favorable. El objetivo del estudio es mostrar el trasplante cardiaco como una opción terapéutica adecuada para pacientes sin respuesta positiva al tratamiento médico. En nuestro centro se ha trasplantado a 3 pacientes con estas características, con un seguimiento medio de 11 ± 2 meses. Ningún paciente falleció y en todos ellos se documentó una reversibilidad de la enteropatía (AU)
Protein-losing enteropathy is a rare but life-threatening complication that occurs in some patients who develop intestinal lymphangiectasis secondary to increased systemic venous pressure. Although different forms of treatment have been tried, with varying results, the majority were reported to be unsuccessful. The aim of this study was to demonstrate that heart transplantation may be an appropriate therapeutic option for patients who do not respond to medical treatment. At our center, we performed heart transplantations in 3 patients with this condition. The mean follow-up period was 11(2) months. No patient died and the enteropathy regressed in all 3 (AU)